The Drugs Controller of India (DCGI) has stepped up its regulatory oversight to curb the unauthorised sale and promotion of GLP-1 weight loss drugs, aiming to ensure ethical practices across the pharmaceutical supply chain. The growing availability of newly introduced generic variants of GLP-1-based weight loss drugs in the Indian market has triggered concerns, particularly as these medications are increasingly accessible through
The only supply chain registration you need
Unrivaled context behind every news and article for free.